BACKGROUND: Increasing body mass index, cholesterol and body fat are associated with a better prognosis in patients with left ventricular systolic dysfunction (LVSD). Beta-blocker usage is associated with changes in body composition and increased body fat. The present study investigated 12-month changes in body composition in patients with LVSD initiated on beta-blocker therapy. METHODS: The relation between beta-blocker use and body composition was evaluated in 91 patients (75% male) with LVSD. Body composition was assessed by bioelectrical impedance. RESULTS: Seventeen patients died during the study period. There was no statistical difference among beta-blocker usage, beta-blocker type, or changes in body fat, basal metabolic rate, impedance, fat-free mass, fat mass and total body water. There were no significant differences between any of these measures and beta-blocker usage. CONCLUSION: After 12 months, changes in body composition were not found to be influenced by initiation of beta-blocker therapy in patients with LVSD.
BACKGROUND: Increasing body mass index, cholesterol and body fat are associated with a better prognosis in patients with left ventricular systolic dysfunction (LVSD). Beta-blocker usage is associated with changes in body composition and increased body fat. The present study investigated 12-month changes in body composition in patients with LVSD initiated on beta-blocker therapy. METHODS: The relation between beta-blocker use and body composition was evaluated in 91 patients (75% male) with LVSD. Body composition was assessed by bioelectrical impedance. RESULTS: Seventeen patients died during the study period. There was no statistical difference among beta-blocker usage, beta-blocker type, or changes in body fat, basal metabolic rate, impedance, fat-free mass, fat mass and total body water. There were no significant differences between any of these measures and beta-blocker usage. CONCLUSION: After 12 months, changes in body composition were not found to be influenced by initiation of beta-blocker therapy in patients with LVSD.
Entities:
Keywords:
Body fat; Chronic heart failure; Fat mass; Fat-free mass
Authors: T O Obisesan; M J Toth; K Donaldson; S S Gottlieb; M L Fisher; P Vaitekevicius; E T Poehlman Journal: Am J Cardiol Date: 1996-06-01 Impact factor: 2.778
Authors: S D Anker; P Ponikowski; S Varney; T P Chua; A L Clark; K M Webb-Peploe; D Harrington; W J Kox; P A Poole-Wilson; A J Coats Journal: Lancet Date: 1997-04-12 Impact factor: 79.321
Authors: Constantinos H Davos; Wolfram Doehner; Mathias Rauchhaus; Mariantonietta Cicoira; Darrel P Francis; Andrew J S Coats; Andrew L Clark; Stefan D Anker Journal: J Card Fail Date: 2003-02 Impact factor: 5.712